News related to Levaquin (Levofloxacin) and/or conditions it is approved for
Mpex Reports Positive Phase II Results With Aeroquin, Delivered By PARI Pharma's EFlow Technology
Source: Cystic Fibrosis News From Medical News Today [2009.09.15]
Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo.
Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results With Aeroquin(R) (MP-376) Treatment In Cystic Fibrosis Patients
Source: Cystic Fibrosis News From Medical News Today [2009.09.11]
Mpex Pharmaceuticals, Inc. announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
|
